Rhode Island Medical Journal, February 2013. rimed.org/rimedicaljournal/2013-02/2013-02-19-bio-epivax.pdf
Recent Posts
- EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services   Â
- Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
- EpiVax Enters its Next Chapter with SV Health Investors
- Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
- Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
Recent Comments
No comments to show.